{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Duration of response for participants is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression or death due to any cause. This analysis was planned but not performed for Part 2 as the study was terminated early during Part 1.","groups":[{"description":"Participants with GCB-DLBCL-mutant and wild type, TFL-mutant and wild type as well as participants with MM were planned to be enrolled in Part 2 of the study. Participants enrolled in Part 2 were planned to receive RP2D .","id":"OG000","title":"Part 2: All Participants"}],"populationDescription":"All Subjects Population. Data was not collected in Part 2 as no participant was enrolled in Part 2.","reportingStatus":"POSTED","timeFrame":"Up to 3.2 years","title":"Part 2: Duration of Response","type":"SECONDARY"}